Evaluate the data from the VIALE-A trial and implications for survival and treatment-related cytopenias.

Outline best practices for response assessment and treatment modifications, including the role of bone marrow biopsies and structured dosing adjustments to manage cytopenias post-remission.

Discuss the impact of collaborative care models in AML management, highlighting how academic-community partnerships can enhance treatment planning, clinical trial access, and overall patient outcomes.